Could cause temporary or reversible harm; serious harm is unlikely.
Sub-potent Drug: Out-of-Specification assay results found at 3 month stability testing.
| Brand name | BUPRENORPHINE HYDROCHLORIDE |
| Generic name | BUPRENORPHINE HYDROCHLORIDE |
| Active ingredient(s) | BUPRENORPHINE HYDROCHLORIDE |
| Distributed by / for | Hikma Pharmaceuticals, Eatontown, NJ 07724, USA Inc |
| NDC | 0143-9246-01 |
| Full product label | Buprenorphine HCl Injection, 0.3 mg/mL, 1 mL vial, For Intramuscular or Intravenous Use Only, Rx Only, Manufactured by: Hikma Farmaceutica, Portugal S.A., Distributed by: Hikma Pharmaceuticals, Eatontown, NJ 07724, USA Inc., NDC: 0143-9246-01. |
| Recalling firm | Hikma Pharmaceuticals USA Inc. |
| Distribution | Nationwide in the U.S. |
| Quantity | 97,890 vials |
| Recall initiated | 2020-08-14 |
| Report date | 2020-09-02 |
| Recall completed | 2021-06-10 |
| Recall number | D-1533-2020 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Cherry Hill NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗